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Abstract
Background:  In general, the Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS)
population has begun to experience the benefits of highly active antiretroviral therapy (HAART); unfortunately, these
benefits have not extended equally to Blacks in the United States, possibly due to differences in patient comorbidities
and demographics. These differences include rates of hepatitis B and C infection, substance use, and socioeconomic
status. To investigate the impact of these factors, we compared hospital mortality and length of stay (LOS) between
Blacks and Whites with HIV/AIDS while adjusting for differences in these key characteristics.
Methods: The 1996–2006 National Hospital Discharge Surveys were used to identify HIV/AIDS patients admitted to
US hospitals. Survey weights were incorporated to provide national estimates. Patients < 18 years of age, those who left
against medical advice, those with an unknown discharge disposition and those with a LOS < 1 day were excluded.
Patients were stratified into subgroups by race (Black or White). Two multivariable logistic regression models were
constructed with race as the independent variable and outcomes (mortality and LOS > 10 days) as the dependent
variables. Factors that were significantly different between Blacks and Whites at baseline via bivariable statistical tests
were included as covariates.
Results: In the general US population, there are approximately 5 times fewer Blacks than Whites. In the present study,
1.5 million HIV/AIDS hospital discharges were identified and Blacks were 6 times more likely to be hospitalized than
Whites. Notably, Blacks had higher rates of substance use (30% vs. 24%; P < 0.001), opportunistic infections (27% vs.
26%; P < 0.001) and cocaine use (13% vs. 5%; P < 0.001). Conversely, fewer Blacks were co-infected with hepatitis C
virus (8% vs. 12%; P < 0.001). Hepatitis B virus was relatively infrequent (3% for both groups). Crude mortality rates were
similar for both cohorts (5%); however, a greater proportion of Blacks had a LOS > 10 days (21% vs. 19%; P < 0.001).
Black race, in the presence of comorbidities, was correlated with a higher odds of LOS > 10 days (OR, 95% CI = 1.20
[1.10–1.30]), but was not significantly correlated with a higher odds of mortality (OR, 95% CI = 1.07 [0.93–1.25]).
Conclusion: Black race is a predictor of LOS > 10 days, but not mortality, among HIV/AIDS patients admitted to US
hospitals. It is possible that racial disparities in hospital outcomes may be closing with time.
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Background
Human Immunodeficiency Virus (HIV) has had a devas-
tating impact on the United States, and the effects are far
reaching. Each year in the United States, HIV infects over
56,000 people and claims upwards of 14,000 lives [1,2].
Despite these grim statistics, there has been considerable
progress made in curbing the detrimental impact of the
epidemic. The introduction of antiretroviral therapy in the
late 1980s was the inaugural event in the therapeutic man-
agement of HIV patients, and led to lower rates of HIV-
related morbidity and mortality [3]. Moreover, the advent
of highly-active antiretroviral therapy (HAART) over a
decade ago resulted in even greater reductions in HIV-
related hospitalizations and mortality [4,5]. While
HAART has decreased overall morbidity and mortality in
the general HIV population, the benefits of these advances
have not extended equally to the Black segment of the
community [6-9].
Many Blacks may first seek care late in the course of their
disease, after they have already become symptomatic with
an opportunistic infection (OI) [10,11]. Because of this
late diagnosis, they are at higher risk for an Acquired
Immunodeficiency Syndrome (AIDS) diagnosis when
they are found to be HIV positive, which may require
immediate hospital admission [12]. Black patients may
then experience longer hospitalizations and higher mor-
tality rates than White patients [13-17]. These disparities
in health outcomes between Black and White HIV patients
may not be attributable to an imbalance in the receipt of
HAART [18].
The presence of these comorbidities may worsen the over-
all health outcomes of those patients with advanced HIV/
AIDS disease even when equivalent therapy is provided
[18-22]. Substance use, hepatitis B virus (HBV), hepatitis
C virus (HCV), and sexually transmitted infections (STIs)
have all been linked to increased transmission of HIV, and
can potentially complicate the course of the HIV disease
[19,21,23-26]. These disparities between the Black HIV/
AIDS population and the non-Black HIV/AIDS popula-
tion are of critical importance; a deeper understanding of
the impact of these disparities in Blacks is needed. To fur-
ther this understanding, the present study evaluated
health outcomes among HIV/AIDS patients in the 1996–
2006 National Hospital Discharge Survey (NHDS). This
study sought to: (1) compare health outcomes (mortality
and length of hospital stay [LOS > 10 days]) between
Black and White patients; (2) describe changes in health
outcomes for Black and White patients over time in the
HAART era; and, (3) quantify baseline rates of OIs, sub-
stance use, HBV, HCV, and STIs for Black and White
patients.
Methods
Data source
Hospital discharge data were extracted from the 1996–
2006 NHDS, a series of annual national surveys con-
ducted by the National Center for Health Statistics
(NCHS) of the Centers for Disease Control and Preven-
tion (CDC) [27]. The NHDS has been conducted annually
since 1965 by the NCHS. The NHDS are a series of volun-
tary nationwide sample surveys completed by short-stay
hospitals in the United States. The NHDS collects infor-
mation from non-federal hospitals (excluding military,
Department of Veterans Affairs, and other federal facilities
such as prison hospitals) in the United States. The US
Bureau of the Census is the agent for data collection for
these surveys. The hospital staff in each facility are trained
by Census personnel to complete the survey instruments.
The units of analyses are national discharges rather than
estimates for individual patients. Some patients may have
multiple discharges from a particular hospital in a given
year and the possibility exists that they may be sampled
more than once, but due to the complexity of the survey
sampling, multiple discharges for an individual patient in
a given year are unlikely. National estimates of diagnoses
and procedures are classified by International Classifica-
tion of Diseases, Ninth Revision, Clinical Modification
(ICD-9) codes. The overall error rate for records manually
coded is estimated at one percent for hospital diagnoses,
0.7 percent for surgical and diagnostic procedures, and 0.2
percent for non-medical data entry [27]. Data from the
NHDS surveys has been used to evaluate other areas of
racial disparities and hospital outcomes [28-30].
Study definitions
An HIV/AIDS-associated hospitalization was defined as a
hospitalization with at least one of the following ICD-9
codes for discharge diagnosis: 042-044 (HIV disease), V08
(asymptomatic HIV infection), or 079.53 (HIV-2 illness).
ICD-9 codes were also collected for diagnoses of HBV,
HCV, substance use, sexually transmitted infections, and
OIs (Table 1). OIs were identified using the conditions
included in the 1993 AIDS surveillance case definition
[31]. Opportunistic infections included: candidiasis, coc-
ciodomycosis, coccidiosis (in place of isosporiasis), crypt-
osporidiosis, cryptococcosis, cytomegalovirus disease,
histoplasmosis,  Mycobacterium Avium, pneumocystosis,
progressive multifocal leukoencephalopathy, Salmonella,
Toxoplasmosis gondii, and tuberculosis [31,32]. Sexually
transmitted infections included chlamydia, gential her-
pes, gonorrhea, herpes simplex virus, human papilloma
virus, Lymphogranuloma venereum, pelvic inflammatory
disease, syphilis, and trichomoniasis. All opportunistic
infections were classified as either preventable with chem-
oprophylaxis (Mycobacterium Avium, pnuemocystosis and
Toxoplasmosis gondii) or non-preventable with chemo-BMC Infectious Diseases 2009, 9:127 http://www.biomedcentral.com/1471-2334/9/127
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Table 1: Codes for Diagnoses from International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM)
ICD-9-CM Code Diagnosis
042, 044, 043, 079.53, V08 Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome
Opportunistic Infections
112 Candidiasis
114 Coccidioidomycosis
007.2 Coccidiosis (for Isosporiasis)
007.4 Cryptosporidiosis
117.5 Cryptococcosis
078.5 Cytomegalovirus
115 Histoplasmosis
031.0, 031.2 Mycobacterium avium
136.3 Pneumocystosis
046.3 Progressive multifocal leukoencephalopathy
003 Salmonella
130 Toxoplasmosis gondii
010-018 Tuberculosis
Hepatitis
070.41, 070.44, 070.51,
070.54, 070.7
Hepatitis C Virus
070.3, 070.2 Hepatitis B Virus
Sexually Transmitted Infections
099.0 Chancroid
099.5 Chlamydia
054 Genital Herpes
098.11, V02.7 Gonorrhea
078.1,079.4, V73.81 Human Papilloma Virus
099.1 Lymphogranuloma venereum
614.9 Pelvic inflammatory disease
091, 092, 093, 094, 095, 095.7, 095.8, 095.9, 096, 097, 097.1, 097.9 SyphilisBMC Infectious Diseases 2009, 9:127 http://www.biomedcentral.com/1471-2334/9/127
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prophylaxis [33]. For the purpose of data analysis, col-
lapsed categories were created for comorbidities that were
reported infrequently. An "other substance use" category
was created for types of substance use with a prevalence of
< 1% and "other STI" for STIs < 1%.
The NHDS surveys provide information about primary
forms of hospital visit payment with standardized
options. For the purposes of data analysis, the different
forms of insurance were defined as uninsured (no charge
or self-pay), government (Medicare, Medicaid, or other
government form of payment), private (HMO/PPO, Blue
Cross/Blue Shield, or other private insurance), and other/
unknown (workers compensation, other, or not stated).
Study design
This was a retrospective analysis of HIV/AIDS hospitaliza-
tions in the United States from 1996–2006. The Univer-
sity of Texas at Austin Institutional Review Board
determined this protocol to be exempt (#2009-03-0100).
Data included patient demographics (age, race, ethnicity,
gender, and marital status), year of discharge, insurance
status, geographic location within the United States, hos-
pital LOS, and discharge status. Patients who were < 18
years, those who left against medical advice, those with an
unknown discharge disposition, and those with a LOS < 1
day were excluded from data analysis. Patient discharge
weighting was incorporated into the dataset to provide
national estimates across the United States.
Hospital mortality and LOS > 10 days were evaluated.
Mortality was classified as an inpatient admission result-
ing in death. In order to incorporate survey weights, LOS
was then dichotomized (mean LOS ≤ 10 or >10 days) for
all hospital discharges. This cut-off was chosen on the
basis of the LOS distribution which demonstrated a peak
of approximately 10 days. Chi-square tests were used to
compare categorical baseline variables (survey year, age,
gender, insurance status, and comorbid conditions)
between races. Two multivariable logistic regression mod-
els were used to assess the impact of race (independent
variable) on hospital mortality and LOS >10 days
131 Trichomoniasis
Types of Substance Use
303, 305.0 Alcohol use
304.3, 305.2 Cannabis use
304.2, 305.6 Cocaine use
304.0, 305.5 Opioid use
305.1 Tobacco use
304.1, 305.4 Sedative, hypnotic, or anxiolytic use
304.5, 305.3 Hallucinogen use
305.7 Amphetamine or related sympathomimetic abuse
305.8 Anti-depressant type abuse
305.9 Other, mixed, or unspecified drug abuse
304.4 Amphetamine and other psychostimulant dependence
304.6 Other specified drug dependence
304.8 Combinations of drug dependence excluding opioid type drug
304.9 Unspecified drug dependence
304.7 Combinations of opioid type drug with any other
Table 1: Codes for Diagnoses from International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) (Continued)BMC Infectious Diseases 2009, 9:127 http://www.biomedcentral.com/1471-2334/9/127
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(dependent variables). Known predictors of poor health
outcomes among HIV patients were entered simultane-
ously as covariates into both models. These included gen-
der, insurance status, AIDS-related infections, and
injection drug use [9,34,35]. The NHDS does not contain
an ICD-9 code for 'injection drug use.' The most detailed
ICD-9 code for heroin use was included under the
umbrella heading of opioid use (which in addition to her-
oin also includes meperidine, morphine, and other opi-
ates). To avoid grouping all types of substance abuse
together, 'cocaine use' was considered a proxy for injec-
tion drug use. Likewise, variables that were statistically
and clinically significant in chi-square analyses were also
entered into both multivariable analyses as covariates.
These variables included race, survey year, age, gender,
insurance status, geographic region, presence of OI, HBV,
HCV, and cocaine use. All data were analyzed using JMP
7.0® (SAS Corp, Cary, NC) and an alpha-level of 0.05 was
used to determine statistical significance.
Results
From 1996–2006, 1.5 million HIV/AIDS hospital dis-
charges were identified. On average, 138,016 hospitaliza-
tions occurred each year. The mean patient age was 42
years and 67% of all patients were male. Blacks accounted
for more hospitalizations than Whites (62% vs. 38%). A
large proportion of patients had government insurance
(66%) or private insurance (22%). Bivariable analyses
(Table 2) revealed a greater proportion of Blacks were
female (41% vs. 21%; P  < 0.001). Chi-square analysis
revealed a significant relationship between insurance sta-
tus and race (P < 0.001); Blacks had a higher likelihood of
having some form of government insurance (70% vs.
58%) and fewer Blacks than Whites had private insurance
(18% vs. 31%).
Comorbidities between Black and White patients
Substance use and OIs were present in 28% and 27% of
all discharges, respectively; whereas HCV, STIs, and HBV
were reported in 10%, 5%, and 3%, respectively. Com-
mon forms of substance use included cocaine use (9%),
alcohol use (9%), opioid use (9%), and tobacco use (6%).
Herpes simplex was not commonly reported (3%).
Results from bivariable analysis of characteristic differ-
ences between Blacks and Whites are reported in Table 2.
A large proportion of both Black and White patients car-
ried diagnoses for OIs (27% vs. 26%; P < 0.001). A signif-
icantly greater proportion of Blacks reported substance
use (30% vs. 24%; P < 0.001). Conversely, fewer patients
in the Black cohort were co-infected with HCV based on
ICD-9 codes (8% vs. 12%;P  < 0.001). The remaining
comorbidities were relatively infrequent among Blacks
and Whites. Further analysis revealed significant differ-
ences for comorbid subtypes between the two cohorts.
Blacks, when compared to Whites, had a higher preva-
lence of non-preventable OI (21% vs. 19%; P < 0.001),
cocaine use (13% vs. 5%; P < 0.001), opioid use (9% vs.
6%; P < 0.001), and alcohol use (10% vs. 8%; P < 0.001).
Hospital mortality between Black and White patients
Overall, crude mortality rates were similar between Black
and White cohorts 5% vs. 5% (OR 95% CI = 0.97 [0.96–
0.99]). Simple logistic regression analysis revealed the fol-
lowing variables (P < 0.001) to be associated with mortal-
ity: race, survey year, age, gender, insurance status,
presence of an OI, HBV, HCV, STIs and cocaine use. All
clinically relevant variables from the regression analysis
were subsequently entered in the multivariable model as
covariates. Results from the multivariable analyses are
presented in Tables 3 and 4. When significant predictors
for mortality were entered into the model, Black race was
not a significant independent predictor of mortality (OR,
95% CI = 1.07 [0.93–1.25], Table 3).
Hospital LOS between Black and White patients
The proportion of patients with LOS > 10 days was higher
for Blacks than Whites (21% vs. 19%; OR, 95% CI = 1.17
[1.16–1.18]). Simple logistic regression analysis revealed
the following variables (P < 0.001) to be associated with
LOS > 10 days: race, survey year, age, gender, insurance
status, presence of OI, HBV, HCV, and cocaine use. All var-
iables from the regression analysis were subsequently
entered in the multivariable model as covariates. Multi-
variable analysis identified Black race as an independent
predictor for LOS > 10 days (OR, 95% CI = 1.20 [1.10–
1.30], Table 4).
Annual hospital mortality and LOS trends between Black 
and White patients
Figure 1 depicts trends in crude hospital mortality for
Blacks and Whites from 1996–2006. Although both
cohorts exhibited decreases in mortality, the decline for
Blacks initially lagged behind that of Whites until 2001,
when rates for mortality appeared to have converged
between the two races. Crude rates for LOS > 10 days were
greater for Blacks at the beginning of the study period, but
the rates for the cohorts appeared to converge with time
(Figure 2). Figures 3 and 4 reflect the adjusted hospital
mortality and LOS trends over the last decade. Similar to
the crude rates, the adjusted rates demonstrate the likeli-
hood of hospital mortality and the likelihood for a longer
LOS for Blacks were initially higher than that of Whites in
1996, but the odds for both outcomes appeared to
decrease with time.
Discussion
This study compared health outcomes for Black and
White HIV/AIDS patients across the United States in the
HAART era. Despite the many successes that have resultedBMC Infectious Diseases 2009, 9:127 http://www.biomedcentral.com/1471-2334/9/127
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from combating the disease over the past decade, pub-
lished data suggest that Blacks continue to experience a
disproportionate burden of HIV infection. Not only are
Blacks overrepresented in the total number of people liv-
ing with the disease, they continue to experience the high-
est rates of new infections and AIDS-related deaths [36].
In the general US population, there are approximately 5
times fewer Blacks than Whites. Of the 1.5 million HIV/
AIDS hospital discharges identified in this study, Blacks
were 6 times more likely to be hospitalized than Whites, a
disparity that has been identified in previous studies con-
ducted after the initiation of HAART [16,17,37]. Although
the crude mortality rates were similar for Blacks and
Whites in the present study, Black race, in the presence of
comorbidities, substance use, and socioeconomic status,
was associated with longer LOS, but not in-hospital mor-
tality. Furthermore, both mortality and LOS seem to have
converged with time. Based on the multivariable regres-
Table 2: Selected Discharge Characteristics among Blacks vs. Whites
Characteristic Total
(N = 1,518,173)
Race P-Value
Blacks
(N = 948,666)
Whites
(N = 569,507)
Survey Year < 0.001
1996 171,253 95,546(10%) 75,707 (13%)
1997 133,493 78,665 (8%) 54,838 (10%)
1998 140,619 82,730 (9%) 57,889 (10%)
1999 125,398 78,075 (8%) 47,323 (8%)
2000 119,673 76,629 (8%) 43,044 (8%)
2001 136,796 93,424 (10%) 43,372 (8%)
2002 134,593 83,645 (9%) 50,948 (9%)
2003 146,975 94,379 (10%) 52,596 (9%)
2004 149,817 92,883 (10%) 56,934 (10%)
2005 121,116 81,165 (9%) 39,951 (7%)
2006 138,440 91,525 (9%) 46,915 (8%)
Age (years) < 0.001
18–34 360,605 224,644 (24%) 135,961 (24%)
35–49 869,517 542,349 (57%) 327,168 (57%)
50–64 258,741 164,579 (17%) 94,162 (17%)
≥ 65 29,310 17,094 (2%) 12,216 (2%)
Gender < 0.001
Male 1,014,194 562,565 (59%) 451,629 (79%)
Female 503,979 386,101 (41%) 117,878 (21%)
Insurance Status < 0.001
Uninsured 135,124 88,389 (9%) 46,735 (8%)
Government 994,492 662,787 (70%) 331,705 (58%)
Private 341,686 167,102 (18%) 175,584 (31%)
Other insurance 46,871 30,388 (3%) 16,483 (3%)
Any Opportunistic Infection (OI) 406,661 255,988 (27%) 150,673 (26%) < 0.001
Preventable OI 167,623 101,043 (11%) 66,580 (12%) < 0.001
Non-Preventable OI 301,316 196,106 (21%) 110,210 (19%) < 0.001
Hepatitis B 47,847 28,051 (3%) 19,796 (3%) < 0.001
Hepatitis C 147,261 80,295 (8%) 66,966(12%) < 0.001
Substance Use 421,591 285,133 (30%) 136,458 (24%) < 0.001
STIs 79,243 54,123 (6%) 25,120 (4%) < 0.001BMC Infectious Diseases 2009, 9:127 http://www.biomedcentral.com/1471-2334/9/127
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sion models, it is possible that other demographic factors
including comorbidities and insurance status may be
more predictive of outcome than simply race.
Although HAART is clearly an effective treatment for HIV,
the clinical benefits of therapy may not extend equally to
patients who are diagnosed with advanced stages of infec-
tions [4,5]. Thus, the high proportion of patients with OIs
was concerning for both study cohorts. Nonetheless,
Black patients demonstrated slightly higher rates of OIs
compared to Whites. This study confirmed that the pres-
ence of an OI was predictive of higher mortality as well as
extended hospitals stays in multivariable regression mod-
els. As previously mentioned, Blacks have been reported
to seek care later in the course of infection after they are
symptomatic from their illness [13-15]. The increased rate
of mortality among Blacks has been well documented
[9,16,23,38]. One such study by Jain and colleagues
Table 3: Mortality Predictors from Multivariable Logistic Regression Analysis
Characteristic OR (95% CI) L-R Chi-Square P-Value
Survey Year 68.2 < 0.001
1996 1.00 (reference)
1997 1.02 (0.63–1.58)
1998 1.25 (0.80–1.89)
1999 1.05 (0.65–1.65)
2000 0.74 (0.43–1.21)
2001 1.19 (0.76–1.83)
2002 0.98 (0.61–1.54)
2003 1.94 (1.29–2.85)
2004 0.59 (0.35–0.96)
2005 0.37 (0.19–0.66)
2006 0.64 (0.38–1.05)
Race 0.9 0.3
White 1.00 (reference)
Black 1.07 (0.93–1.25)
Age (years) 12.8 0.005
18–34 1.00 (reference)
35–49 0.66 (0.51–0.86)
50–64 0.77 (0.55–1.08)
≥ 65 3.06 (1.65–5.37)
Gender 2.7 0.9
Female 1.00 (reference)
Male 1.14 (0.98–1.34)
Insurance Status 3.8 0.4
Uninsured 1.00 (reference)
Government 0.81 (0.63–1.07)
Private 0.76 (0.55–1.04)
Other insurance 1.57 (0.85–2.74)
Presence of Comorbidities*
Preventable OI 2.39 (2.00–2.83) 86.9 < 0.001
Non-preventable OI 1.16 (0.98–1.37) 3.1 0.08
HBV 0.86 (0.54–1.31) 0.5 0.5
HCV 0.85 (0.64–1.11) 1.3 0.2
Cocaine use 0.46 (0.32–0.80) 25.2 < 0.001
*Reference group is the absence of a comorbidity where OR = 1.00BMC Infectious Diseases 2009, 9:127 http://www.biomedcentral.com/1471-2334/9/127
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reported poorer outcomes among patients with OIs, spe-
cifically highlighting the elevated risk for Black patients
[34]. The Jain study differs from the present study in that
the investigators were unable to evaluate comorbidities,
and various forms of substance use.
Baseline rates of substance use were higher among Blacks
than Whites. The rate of cocaine use for Blacks was almost
three times that of Whites; interestingly, regression analy-
sis revealed cocaine use was 'protective' for mortality, per-
haps because cocaine use was also associated with
younger age. Nevertheless, studies suggest illicit drug use
may have a negative impact on the treatment and course
of HIV/AIDS infection [39,40]. Concomitant use of illicit
substances may also interfere with a patients' ability to
adhere to antiretroviral regimens, thereby placing them at
risk for poorer health outcomes [23,39,40]. Cocaine has
been demonstrated in vitro and in experimental animal
Table 4: Predictors for LOS > 10 days from Multivariable Logistic Regression Analysis
Characteristic OR (95% CI) L-R Chi-Square P-Value
Survey Year 104.4 < 0.001
1996 1.00 (reference)
1997 1.78 (1.41–2.25)
1998 1.47 (1.17–1.86)
1999 0.62 (0.47–0.81)
2000 0.94 (0.72–1.22)
2001 0.91 (0.71–1.17)
2002 0.91 (0.71–1.17)
2003 1.07 (0.85–1.36)
2004 0.74 (0.58–0.95)
2005 0.65 (0.49–0.86)
2006 0.72 (0.56–0.93)
Race 18.4 < 0.001
White 1.00 (reference)
Black 1.20 (1.10–1.30)
Age 26.4 < 0.001
18–34 1.00 (reference)
35–49 0.98 (0.83–1.17)
50–64 1.34 (1.09–1.64)
≥ 65 1.10 (0.70–1.67)
Gender 0.3 0.6
Female 1.00 (reference)
Male 1.02 (0.94–1.11)
Insurance Status 8.4 0.04
Uninsured 1.00 (reference)
Government 1.22 (1.04–1.43)
Private 0.96 (0.80–1.16)
Other insurance 0.89 (0.62–1.27)
Presence of Comorbidities*
Preventable OI 1.97 (1.77–2.20) 142.9 < 0.001
Non-preventable OI 2.03 (1.86–2.22) 238.0 < 0.001
HBV 1.05 (0.84–1.31) 0.2 0.7
HCV 1.04 (0.90–1.19) 0.3 0.6
Cocaine use 0.98 (0.93–1.12) 0.1 0.8
*Reference group is the absence of a comorbidity where OR = 1.00BMC Infectious Diseases 2009, 9:127 http://www.biomedcentral.com/1471-2334/9/127
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models to enhance viral replication and interfere with the
body's ability to defend itself naturally against infection.
This may hasten disease progression and the development
of AIDS-defining conditions, even among patients who
are adherent to antiretroviral therapy [41-43]. However,
definitive data directly implicating illicit drug use as a
causative factor in increased HIV susceptibility or disease
progression remain elusive [41]. Of the various types of
substance use in this study, cocaine use was the most
likely form of injection drug use, which has also been
implicated in the transmission of not only HIV, but also
HBV and HCV, particularly among minority populations
[23-25].
Beyond the HIV/AIDS population, other racial disparities
exist for Blacks; they tend to have higher rates of HBV and
HCV compared to Whites [24,25,44]. Furthermore,
response to therapy for HCV is markedly diminished for
Blacks [45]. Interestingly, in the present study the rates of
HBV coinfection were similar among both study cohorts
and HCV coinfection rates were lower for Blacks than for
Whites. Although hepatitis coinfection is associated with
increased mortality, the true rates of HIV/HCV coinfection
and its implications for health outcomes among Black
populations remain ill-defined [26,46].
Likewise, the national impact of race disparities among
individuals with concomitant STIs is not well-character-
ized [47]. The increased risk for contracting HIV with
Crude hospital mortality for Black and White HIV/AIDS  patients from 1996–2006 Figure 1
Crude hospital mortality for Black and White HIV/
AIDS patients from 1996–2006.
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Crude LOS > 10 days for Black and White HIV/AIDS patients  from 1996–2006 Figure 2
Crude LOS > 10 days for Black and White HIV/AIDS 
patients from 1996–2006.
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simultaneous STIs (both ulcerative and non ulcerative)
has been well established [47-50]. HIV, coupled with
infections such as syphilis, may negatively impact the
immune status of the individual and may lead to higher
rates of treatment failure [19,51,52]. Furthermore, genital
herpes, gonorrhea, chlamydia, syphilis, bacterial vagino-
sis and chancroid, are reportedly higher in minority pop-
ulations [47]. In the present study, reported rates of STIs
were relatively low in both groups of hospitalized
patients. Complications from STIs including severe herpes
simplex virus, syphilis with neurologic involvement, and
acute pelvic inflammatory may require aggressive treat-
ment necessitating hospitalization, whereas most other
STIs can be managed effectively in the ambulatory setting
[53]. Therefore, STIs were not included in regression anal-
yses. Definitive conclusions regarding STIs could not be
made from this cohort of hospitalized patients. Neverthe-
less, a higher percentage of Blacks carried an STI ICD-9
diagnosis.
A surprising, but fortunate finding from this study is the
possibility that racial disparities in hospital outcomes
may be closing with time. This possible reduction in racial
disparities in outcome has been demonstrated elsewhere
[8,37,54,55]. Similar to the Giordano and Hlaing studies,
this study was not able to incorporate antiretroviral use in
the regression analysis [37,55]. Antiretrovirals, if pre-
scribed properly, may reduce differences in outcomes
between Blacks and Whites [8,54]. Yet, in stark contrast,
Jain and colleagues concluded that the disparity for higher
mortality for Black HIV patients has actually widened in
the HAART era [34]. According to their results, the ele-
vated risk of a poor outcome was also attributable to the
presence of an opportunistic infection, a finding that is
consistent with the present study. Another study by Levine
and colleagues also substantiates these findings. They
identified that higher rates of mortality existed among
Black males both before and after the introduction of
HAART [9]. The investigators lacked data for comorbid
conditions and also did not evaluate hospitalized
patients. The current study evaluated all-cause hospital
mortality, whereas the two studies that concluded Blacks
were at increased risk for mortality used surveillance data
and a combination of inpatient and outpatient data
[56,57]. The present study had the most patient records
and the longest duration of any of the studies identified in
the literature review.
This study shares the limitations of all retrospective cohort
studies. In addition, the analysis was limited by the lack of
available clinical variables, including medication infor-
mation, time of HIV diagnosis, and objective clinical
markers of disease progression. Therefore, we could not
assess the relationships between quality of care indicators
and patient outcomes. Additionally, management of
acute HBV, HCV, and STIs may not require hospitaliza-
tion. These data are also limited by proxies for racism and
discrimination that are known predictors of racially-
biased outcomes. These variables are important when
describing disparities and could have at least partly
explained the racial variations and/or non-variations
found in this study. The data source lacks information
regarding patients of Hispanic descent; therefore, we were
unable to draw conclusions about health disparities for
this minority group that is also facing a disproportionate
burden of HIV [36]. Another limitation is that patients
who were admitted for less than one day, or who left the
hospital against medical advice were excluded from the
analysis. It is possible these patients ultimately suffered
suboptimal health outcomes (early mortality). The survey
scope encompassed only non-federal hospitals, so the
Adjusted LOS > 10 days for Black vs. White HIV/AIDS  patients from 1996–2006 (Odds Ratio, 95% CI)* Figure 4
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results may not be applicable to HIV/AIDS patients admit-
ted to other US hospitals, such as the Veterans Healthcare
Administration. Finally, several other complex socioeco-
nomic issues that may affect health outcomes were not
evaluated in this study.
Conclusion
This study characterized the rates of comorbid conditions,
hospital mortality and LOS, and evaluated trends in
health outcomes among Black and White HIV/AIDS
patients over a decade. Some disparities may still persist
despite the availability of effective interventions to reduce
morbidity and mortality. This national assessment of hos-
pital discharges demonstrates that Black race may be pre-
dictive of longer LOS, but not mortality. In addition,
disparities in health outcomes may be decreasing with
time. Further research efforts are warranted to recognize
and clarify the complexities facing the Black HIV/AIDS
population in order to reduce health disparities.
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